ArticleExpert opinion on investigational drugs2021
Repurposing elesclomol, an investigational drug for the treatment of copper metabolism disorders.
Article in Expert opinion on investigational drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 52 citations in OpenAlex.
- m6A Modification of ATOX1 Inhibits Acute Myeloid Leukemia Progression by Promoting Cuproptosis.Cancer research communications · 2026Article
- Dynamic PET Imaging of Elesclomol-Facilitated Copper Delivery in Ischemic Stroke Rats.ACS omega · 2026Article
- Feeding-Triggered Seizures in a Newborn withJournal of clinical medicine · 2025Article
- Engineering Inorganic Nanoparticles to Induce Cuproptosis: A New Strategy for Cancer Therapy.Pharmaceutics · 2025Review
- Article
- A primer on copper biology in the brain.Neurobiology of disease · 2025Review
- Review
- Elesclomol rescues mitochondrial copper deficiency in disease models without triggering cuproptosis.The Journal of pharmacology and experimental therapeutics · 2025Article
- Mammalian copper homeostasis: physiological roles and molecular mechanisms.Physiological reviews · 2025Review
- Cuproptosis: a promising new target for breast cancer therapy.Cancer cell international · 2024Review
- Thioamides in medicinal chemistry and as small molecule therapeutic agents.European journal of medicinal chemistry · 2024Review
- Review to Elucidate the Correlation between Cuproptosis-Related Genes and Immune Infiltration for Enhancing the Detection and Treatment of Cervical Cancer.International journal of molecular sciences · 2024Review
- GlialProceedings of the National Academy of Sciences of the United States of America · 2024Article
- Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives.Journal of hematology & oncology · 2024Review
- Cuproptosis: Unraveling the Mechanisms of Copper-Induced Cell Death and Its Implication in Cancer Therapy.Cancers · 2024Review
- Targeting the initiator to activate both ferroptosis and cuproptosis for breast cancer treatment: progress and possibility for clinical application.Frontiers in pharmacology · 2024Review
- The Tao of Copper Metabolism: From Physiology to Pathology.Current medicinal chemistry · 2024Review
- Elesclomol, a copper-transporting therapeutic agent targeting mitochondria: from discovery to its novel applications.Journal of translational medicine · 2023Review
- In vitro and in vivo characterization of [European journal of nuclear medicine and molecular imaging · 2023Article
- Copper metabolism in cell death and autophagy.Autophagy · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.